Estrogen receptor β1 in diffuse large B-cell lymphoma growth and as a prognostic biomarker

Research output: Contribution to journalArticle

Abstract

Diffuse large B-cell lymphoma (DLBCL) shows a higher incidence in males versus females. Epidemiological studies have shown that female gender is a favorable prognostic factor, which may be explained by estrogens. Here we show that when grafting human DLBCL cells to immunocompromised mice, tumor growth in males is faster. When treating mice grafted with either germinal center or activated B-cell like DLBCL cells with the selective estrogen receptor β (ERβ) agonist diarylpropionitrile, tumor growth was significantly inhibited. Furthermore, nuclear ERβ1 expression analysis in primary DLBCL’s by immunohistochemistry revealed expression in 89% of the cases. Nuclear ERβ1 expression was in a univariate and multivariate analysis, an independent prognostic factor for adverse progression-free survival in Rituximab-chemotherapy treated DLBCL (p = 0.02 and p = 0.04, respectively). These results suggest that estrogen signaling through ERβ1 is an interesting future therapeutic target for treatment of DLBCL, and that ERβ1 expression can be used as a prognostic marker.

Details

Authors
  • Muhammad Sharif Hasni
  • Mattias Berglund
  • Konstantin Yakimchuk
  • Jiyu Guan
  • Johan Linderoth
  • Rose-Marie Amini
  • Gunilla Enblad
  • Sam Okret
Organisations
External organisations
  • Karolinska Institutet
  • Skåne University Hospital
  • Uppsala University
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Cancer and Oncology

Keywords

  • Estrogen, gender difference, immunohistochemistry, lymphoma growth, receptor expression
Original languageEnglish
Pages (from-to)418-427
Number of pages10
JournalLeukemia & Lymphoma
Volume58
Issue number2
Publication statusPublished - 2017 Feb 1
Publication categoryResearch
Peer-reviewedYes